Metabolic reprogramming in colorectal cancer: regulatory networks and therapy
Abstract With high prevalence and mortality, together with metabolic reprogramming, colorectal cancer is a leading cause of cancer-related death. Metabolic reprogramming gives tumors the capacity for long-term cell proliferation, making it a distinguishing feature of cancer. Energy and intermediate...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-02-01
|
| Series: | Cell & Bioscience |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13578-023-00977-w |
| _version_ | 1811165690462208000 |
|---|---|
| author | Jieping Zhang Shaomin Zou Lekun Fang |
| author_facet | Jieping Zhang Shaomin Zou Lekun Fang |
| author_sort | Jieping Zhang |
| collection | DOAJ |
| description | Abstract With high prevalence and mortality, together with metabolic reprogramming, colorectal cancer is a leading cause of cancer-related death. Metabolic reprogramming gives tumors the capacity for long-term cell proliferation, making it a distinguishing feature of cancer. Energy and intermediate metabolites produced by metabolic reprogramming fuel the rapid growth of cancer cells. Aberrant metabolic enzyme-mediated tumor metabolism is regulated at multiple levels. Notably, tumor metabolism is affected by nutrient levels, cell interactions, and transcriptional and posttranscriptional regulation. Understanding the crosstalk between metabolic enzymes and colorectal carcinogenesis factors is particularly important to advance research for targeted cancer therapy strategies via the investigation into the aberrant regulation of metabolic pathways. Hence, the abnormal roles and regulation of metabolic enzymes in recent years are reviewed in this paper, which provides an overview of targeted inhibitors for targeting metabolic enzymes in colorectal cancer that have been identified through tumor research or clinical trials. |
| first_indexed | 2024-04-10T15:40:43Z |
| format | Article |
| id | doaj.art-2e8af8c80ee34812a8afed0827d79974 |
| institution | Directory Open Access Journal |
| issn | 2045-3701 |
| language | English |
| last_indexed | 2024-04-10T15:40:43Z |
| publishDate | 2023-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Cell & Bioscience |
| spelling | doaj.art-2e8af8c80ee34812a8afed0827d799742023-02-12T12:23:51ZengBMCCell & Bioscience2045-37012023-02-0113112110.1186/s13578-023-00977-wMetabolic reprogramming in colorectal cancer: regulatory networks and therapyJieping Zhang0Shaomin Zou1Lekun Fang2Department of General Surgery, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital, Sun Yat-Sen UniversityDepartment of General Surgery, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital, Sun Yat-Sen UniversityDepartment of General Surgery, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital, Sun Yat-Sen UniversityAbstract With high prevalence and mortality, together with metabolic reprogramming, colorectal cancer is a leading cause of cancer-related death. Metabolic reprogramming gives tumors the capacity for long-term cell proliferation, making it a distinguishing feature of cancer. Energy and intermediate metabolites produced by metabolic reprogramming fuel the rapid growth of cancer cells. Aberrant metabolic enzyme-mediated tumor metabolism is regulated at multiple levels. Notably, tumor metabolism is affected by nutrient levels, cell interactions, and transcriptional and posttranscriptional regulation. Understanding the crosstalk between metabolic enzymes and colorectal carcinogenesis factors is particularly important to advance research for targeted cancer therapy strategies via the investigation into the aberrant regulation of metabolic pathways. Hence, the abnormal roles and regulation of metabolic enzymes in recent years are reviewed in this paper, which provides an overview of targeted inhibitors for targeting metabolic enzymes in colorectal cancer that have been identified through tumor research or clinical trials.https://doi.org/10.1186/s13578-023-00977-wColorectal cancerMetabolic reprogrammingMetabolic enzymesSignal transductionTargeted therapy |
| spellingShingle | Jieping Zhang Shaomin Zou Lekun Fang Metabolic reprogramming in colorectal cancer: regulatory networks and therapy Cell & Bioscience Colorectal cancer Metabolic reprogramming Metabolic enzymes Signal transduction Targeted therapy |
| title | Metabolic reprogramming in colorectal cancer: regulatory networks and therapy |
| title_full | Metabolic reprogramming in colorectal cancer: regulatory networks and therapy |
| title_fullStr | Metabolic reprogramming in colorectal cancer: regulatory networks and therapy |
| title_full_unstemmed | Metabolic reprogramming in colorectal cancer: regulatory networks and therapy |
| title_short | Metabolic reprogramming in colorectal cancer: regulatory networks and therapy |
| title_sort | metabolic reprogramming in colorectal cancer regulatory networks and therapy |
| topic | Colorectal cancer Metabolic reprogramming Metabolic enzymes Signal transduction Targeted therapy |
| url | https://doi.org/10.1186/s13578-023-00977-w |
| work_keys_str_mv | AT jiepingzhang metabolicreprogrammingincolorectalcancerregulatorynetworksandtherapy AT shaominzou metabolicreprogrammingincolorectalcancerregulatorynetworksandtherapy AT lekunfang metabolicreprogrammingincolorectalcancerregulatorynetworksandtherapy |